Provention Bio Inc (NASDAQ:PRVB) was the recipient of a significant growth in short interest during the month of June. As of June 30th, there was short interest totalling 1,023,000 shares, a growth of 27.3% from the May 30th total of 803,900 shares. Based on an average trading volume of 829,600 shares, the days-to-cover ratio is presently 1.2 days. Approximately 4.2% of the shares of the stock are sold short.
A number of research analysts have recently commented on the stock. Chardan Capital assumed coverage on shares of Provention Bio in a report on Monday, June 10th. They issued a “buy” rating and a $20.00 target price for the company. Zacks Investment Research cut shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 16th. Finally, HC Wainwright reissued a “buy” rating on shares of ACASTI PHARM-TS in a report on Wednesday, June 26th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Provention Bio currently has an average rating of “Buy” and a consensus price target of $12.19.
In related news, insider Ashleigh Palmer bought 4,000 shares of the company’s stock in a transaction dated Tuesday, June 18th. The stock was purchased at an average price of $10.83 per share, with a total value of $43,320.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Anthony Digiandomenico bought 25,000 shares of the company’s stock in a transaction dated Monday, June 17th. The stock was bought at an average cost of $12.16 per share, with a total value of $304,000.00. The disclosure for this purchase can be found here. Insiders bought 39,000 shares of company stock valued at $456,920 in the last three months. Company insiders own 19.60% of the company’s stock.
NASDAQ PRVB traded up $0.73 during trading hours on Friday, reaching $12.00. The company’s stock had a trading volume of 292,729 shares, compared to its average volume of 552,451. The company’s fifty day simple moving average is $9.22. The firm has a market capitalization of $448.32 million and a PE ratio of -10.08. Provention Bio has a 52 week low of $1.52 and a 52 week high of $22.82.
Provention Bio (NASDAQ:PRVB) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.11). As a group, sell-side analysts expect that Provention Bio will post -1.19 earnings per share for the current year.
About Provention Bio
Provention Bio, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics and cutting-edge solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, oral CSF-1R inhibitor, which is in Phase 2a clinical trial for the treatment of Crohn's disease; PRV-300, anti-TLR3 mAb, which is in Phase 1b clinical trial for the treatment of ulcerative colitis; PRV-3279 for the treatment of lupus; and PRV-101, a multivalent coxsackie virus vaccine for the prevention of acute Coxsackie Virus B Vaccine and the prevention of the onset of T1D.
Featured Article: What does a bar chart mean for investors?
Receive News & Ratings for Provention Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Provention Bio and related companies with MarketBeat.com's FREE daily email newsletter.